知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.015 seconds)

    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
    8.
    发明申请
    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 有权
    CYCEGEGALOVIRUS矢量控制T细胞靶向

    公开(公告)号：US20160010112A1

    公开(公告)日：2016-01-14

    申请号：US14773130

    申请日：2014-03-05

    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY

    Inventor： Louis Picker ,  Scott Hansen ,  Klaus Frueh ,  Daniel Malouli

    IPC: C12N15/86 ,  A61K39/04 ,  C12N7/00 ,  A61K39/21

    CPC classification number: C12N15/86 ,  A61K39/04 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16011 ,  C12N2710/16143 ,  C12N2740/15034

    Abstract: Disclosed herein are CMV vectors that include a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL128 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an ortholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II.

    Abstract translation: 本文公开了包含异源蛋白质抗原，活性UL131蛋白（或其直系同源物），活性UL128蛋白（或其直系同源物），但其中CMV载体缺少活性UL130蛋白（或其直系同源物）的CMV载体， 。 本文还公开了包含：异源蛋白抗原，活性UL131蛋白（或其直系同源物），活性UL130蛋白（或其直系同源物），但其中CMV载体缺少活性UL128蛋白的CMV载体。 进一步公开的是使用CMV载体产生特征为具有至少10％的CD8 + T细胞针对MHC II类呈递的表位的免疫应答的方法。

    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
    9.
    发明申请
    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 审中-公开

    公开(公告)号：US20180087069A1

    公开(公告)日：2018-03-29

    申请号：US15693558

    申请日：2017-09-01

    Applicant: Oregon Health & Science University

    Inventor： Louis Picker ,  Scott Hansen ,  Klaus Frueh ,  Daniel Malouli

    IPC: C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K39/04 ,  C12N7/00 ,  A61K48/00 ,  A61K39/00

    CPC classification number: C12N15/86 ,  A61K39/04 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16011 ,  C12N2710/16143 ,  C12N2740/15034

    Abstract: CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.A clean version of the amended Abstract is provided below:CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.

Patent Agency Ranking